Search
Phenyl salicylate
go.drugbank.com/drugs/DB11071ApprovedThese are polycyclic compounds that is either a polyphenolic compound composed of two or more monocyclic aromatic units linked by an ester bond (depside), or a compound containing the depsidone structure … This compound belongs to the class of organic compounds known as depsides and depsidones.
Fasedienol
go.drugbank.com/drugs/DB04968InvestigationalIt is a member of a new family of pharmaceutical compounds called vomeropherins. … PH94B is being developed by Pherin Pharmaceuticals, Inc. for the treatment of social phobias (generalized anxiety disorder).
C11-12 isoparaffin
go.drugbank.com/drugs/DB11329ApprovedC11-12 isoparaffin is a mixture of branched chain hydrocarbons with 11C or 12C's in the alkyl chain. It is found in cosmetic and personal care products as solvents or skin conditioning agent.
Heme arginate
go.drugbank.com/drugs/DB17310InvestigationalCategories: Heterocyclic Compounds with 4 or More RingsDrotebanol
go.drugbank.com/drugs/DB01547ExperimentalIllicitCategories: Heterocyclic Compounds with 4 or More RingsClorgiline
go.drugbank.com/drugs/DB04017ExperimentalAn antidepressive agent and monoamine oxidase inhibitor related to PARGYLINE.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeNisin Z
go.drugbank.com/drugs/DB19122InvestigationalNisin Z is under investigation in clinical trial NCT06097468 (Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC)).
Categories: Compounds used in a research, industrial, or household settingRemacemide
go.drugbank.com/drugs/DB06458ExperimentalCategories: Compounds used in a research, industrial, or household settingAminacrine
go.drugbank.com/drugs/DB11561InvestigationalA highly fluorescent anti-infective dye used clinically as a topical antiseptic and experimentally as a mutagen, due to its interaction with DNA. It is also used as an intracellular pH indicator.
Categories: Compounds used in a research, industrial, or household settingBebtelovimab
go.drugbank.com/drugs/DB16755ApprovedWithdrawn[L40328] Bebtelovimab was issued an emergency use authorization (EUA) by the FDA on February 11, 2022, for the treatment of mild-to-moderate COVID-19 in select patients. … [L40313] In November 2022, the FDA updated the Health Care Provider Fact Sheet for bebtelovimab to inform of its expected reduced activity against certain emerging Omicron subvariants of SARS-CoV-2.